HIV prevention drug hailed as breakthrough, but who gets access?

The medical landscape of HIV prevention could be radically reshaped following clinical trials demonstrating that lenacapavir, a twice-yearly injectable antiretroviral, offers near-complete protection against the virus. For nations across sub-Saharan Africa, where public health systems continue to battle high transmission rates, the drug represents the closest scientific advance to an effective vaccine in over a decade. Yet, as health advocates celebrate this scientific milestone, an intense global debate has emerged regarding equitable access, intellectual property rights, and the staggering disparities in drug pricing between wealthy nations and the Global South. Developed by United States pharmaceutical giant Gilead Sciences, lenacapavir has faced heavy criticism from humanitarian organizations like Doctors Without Borders (MSF). While the medication is commercialized in the US at an exorbitant annual cost of roughly $28,000 per patient, generic manufacturers are expected to produce equivalent versions for approximately $40 a year. However, restrictive licensing terms and patent exclusions have left several low- and middle-income countries scrambling to secure affordable pathways for mass distribution. Public health experts argue that excluding certain developing regions from generic manufacturing agreements is deeply unethical, particularly when clinical trial data from African cohorts laid the groundwork for the drug's approval. In Zambia and neighboring countries, the arrival of lenacapavir coincides with a delicate juncture marked by tightening international health budgets and declining donor assistance. According to recent reports from UNAIDS, global HIV funding fell significantly, placing immense strain on domestic prevention and treatment programmes. While Gilead has pledged no-profit supplies through partnerships with organizations like PEPFAR and the Global Fund—with initial rollouts planned for Zambia, South Africa, Kenya, and other high-burden nations